AARTIPHARM.BOAARTIPHARM.BOBSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+33.9%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+33.9%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
2.4x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$4.74B+21.4%
2024$3.91B+13.5%
2023$3.44B+74.1%
2022$1.98B+4304693.1%
2021$-45960.00-
2020$0.00-